Imlunestrant Improves PFS Among Patients with ESR1-mutated ER-positive, HER2-negative ABC and In Combination with Abemaciclib Regardless of ESR1 Mutation Status By Ogkologos - December 17, 2024 546 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EMBER-3 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Lorlatinib in First-Line Treatment of Patients with Advanced ALK-Positive NSCLC With... May 30, 2022 Νέα διαγνωστική μέθοδος για τον καρκίνο, με τη συμβολή της Microsoft August 5, 2019 The Combination of Nivolumab and Cabozantinib Provides a New First-Line Treatment... September 19, 2020 Virtual Reality Found to Benefit Cancer Patients’ Mental Health October 15, 2021 Load more HOT NEWS Tyrosine Kinase Inhibitor Prolongs Progression-Free Survival in Rare Neuroendocrine Tumours [ESMO... Drug Combination May Have Potential for Cancers with TP53 Mutations Mom Of Three Fought Breast Cancer, Drought, And Australia Bushfires In... Chemo before surgery helps stop colon cancer coming back
